RxDoctor Payments Data

Santiago Pompa

Psychiatric/Mental Health · Edinburg, TXNPI 1316302342

Payments from drug & device makers

$874in general payments, 2019–2025

Across 37 payments — averaging $23.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$185
  • Alkermes, Inc.$175
  • Otsuka America Pharmaceutical, Inc.$118
  • Teva Pharmaceuticals USA, Inc.$83
  • AbbVie$77
  • Johnson & Johnson$69
  • plus $167 from 7 others

What the payments were for

  • Food & beverage$874100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$874 in reported general payments places this provider in the 55th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$2,417
Medicare patients
28
Services billed
53

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate24$251,874
Invega SustennaPaliperidone Palmitate51$169,057
VraylarCariprazine Hcl36$51,020
Abilify MaintenaAripiprazole11$33,054
Lurasidone Hcl118$26,724
LybalviOlanzapine/Samidorphan Malate14$22,821
Paliperidone ErPaliperidone12$6,431
Clozapine OdtClozapine12$5,325
Clozapine20$5,195
Trazodone Hcl198$3,548
Quetiapine Fumarate209$3,406
Doxepin Hcl58$2,381
Venlafaxine Hcl ErVenlafaxine Hcl120$2,085
Benztropine Mesylate119$2,084
Hydroxyzine Hcl73$2,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$69$420,93175 claims
AbbVieVraylar$77$51,02036 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$118$33,05411 claims
Alkermes, Inc.Lybalvi$175$22,82114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Edinburg

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →